RxDoctor Payments Data

William Covell, MD

Internal Medicine · Middletown, DENPI 1336222017

Payments from drug & device makers

$478in general payments, 2019–2025

Across 19 payments — averaging $25.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$103
  • Inspire Medical Systems, Inc.$102
  • AbbVie$62
  • Phadia US Inc.$46
  • Insightec,inc$35
  • Sanofi Pasteur Inc.$29
  • plus $102 from 6 others

What the payments were for

  • Food & beverage$478100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$478 in reported general payments places this provider in the 70th percentile of 477 internal medicine providers in Delaware.

See all internal medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$65,193
Medicare patients
204
Services billed
1,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$49,594
XareltoRivaroxaban35$41,048
TrulicityDulaglutide11$21,810
OzempicSemaglutide20$21,583
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$18,841
JardianceEmpagliflozin21$16,144
Breo ElliptaFluticasone/Vilanterol16$13,233
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$4,637
LantusInsulin Glargine,hum.Rec.Anlog11$2,562
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,276
Atorvastatin Calcium274$2,092
Albuterol Sulfate HfaAlbuterol Sulfate56$1,850
Levothyroxine Sodium220$1,794
Losartan Potassium219$1,550
Gabapentin78$1,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$103$32,07436 claims
AbbVieSynthroid$62$1,48325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 477 internal medicine providers in Delaware.

Other internal medicine in Middletown

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →